AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10505830 — intervention group
Group type: EXPERIMENTAL
Intervention: Light reduction intervention
Number of subjects: 0
Study 10505830 — intervention group
Group type: COMPARATOR
Intervention: Control group (ambient light exposure)
Number of subjects: 0
Study 8565755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy
Number of subjects: 48
Study 8565755 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 48
Study 2021720 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographers' assessments using a four point triage scheme (normal, abnormal, insignificantly abnormal, or further advice required)
Number of subjects: 3394
Study 2021720 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographers' assessments
Number of subjects: 3394
Study 31709452 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched environmental programme
Number of subjects: 92
Study 31709452 — intervention group
Group type: COMPARATOR
Intervention: Usual ward activity
Number of subjects: 92
Study 30484021 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-cupping therapy
Number of subjects: 180
Study 30484021 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (rest and oral medications)
Number of subjects: 180
Study 28974480 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PFAS concentrations (PFOS and PFOA)
Number of subjects: 957
Study 23993038 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided paresis group
Number of subjects: 42
Study 23993038 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided paresis group
Number of subjects: 42
Study 23993038 — intervention group
Group type: COMPARATOR
Intervention: Historical control subjects
Number of subjects: 42
Study 23601029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual mucosa graft urethroplasty
Number of subjects: 30
Study 23601029 — intervention group
Group type: COMPARATOR
Intervention: Buccal mucosa graft urethroplasty
Number of subjects: 30
Study 21425572 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiongshao Capsule (XSC)
Number of subjects: 240
Study 21425572 — intervention group
Group type: COMPARATOR
Intervention: Xuefu Zhuyu Capsule (Control)
Number of subjects: 240
Study 21714585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg (group R)
Number of subjects: 90
Study 21714585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus fenofibrate 200 mg (group RF)
Number of subjects: 90
Study 21714585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (group RΩ)
Number of subjects: 90
Study 17402355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group using a portable computer for daily contact with heart failure clinic
Number of subjects: 60
Study 17402355 — intervention group
Group type: COMPARATOR
Intervention: Usual ambulatory care
Number of subjects: 60
Study 16215713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg/day)
Number of subjects: 39
Study 16215713 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day) + Metoprolol (50 mg/day)
Number of subjects: 39
Study 16215713 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 39
Study 16215713 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug therapy groups
Number of subjects: 39
Study 16215713 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 39
Study 11897539 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 25
Study 11897539 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 25
Study 10543315 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142633F 1.0 mg
Number of subjects: 56
Study 10543315 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142633F 3.0 mg
Number of subjects: 56
Study 10543315 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142633F 30 mg
Number of subjects: 56
Study 10543315 — intervention group
Group type: EXPERIMENTAL
Intervention: PNU-142633F 100 mg
Number of subjects: 56
Study 10543315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7587604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with glurenorm and insulin
Number of subjects: 33
Study 7587604 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 33
Study 7587604 — intervention group
Group type: COMPARATOR
Intervention: Glurenorm
Number of subjects: 33
Study 2339203 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (marine oil capsules)
Number of subjects: 20
Study 2339203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (daily dosages increasing from 162 to 2600 mg)
Number of subjects: 20
Study 2339203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6106735 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal polysaccharide vaccine
Number of subjects: 827
Study 6106735 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Haemophilus influenzae type b capsular polysaccharide)
Number of subjects: 827
Study 31437191 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurements during low-intensity resistance exercises (half squat, 45 inclined leg press, leg extension, horizontal bench press, 45 inclined bench press, lat pull down, triceps extension, biceps curl)
Number of subjects: 56
Study 28540899 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 193
Study 28540899 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 193
Study 25791863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 57 g/d of pistachios daily)
Number of subjects: 54
Study 25791863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 54
Study 25791863 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 54
Study 22920910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 76
Study 22920910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 21098143 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem alone
Number of subjects: 0
Study 21098143 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem after 15 days of 400 mg carbamazepine
Number of subjects: 0
Study 19830963 — intervention group
Group type: EXPERIMENTAL
Intervention: ScotchBond Multi‐Purpose (MP, 3M ESPE)
Number of subjects: 39
Study 19830963 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental adhesive (EX, Vericom) with retention form
Number of subjects: 39
Study 19830963 — intervention group
Group type: EXPERIMENTAL
Intervention: All adhesives with retention form
Number of subjects: 39
Study 19830963 — intervention group
Group type: COMPARATOR
Intervention: Adper Prompt (AP, 3M ESPE)
Number of subjects: 39
Study 16918657 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg x kg(‐1) administered i.v. before intubation (Group R, n = 59)
Number of subjects: 119
Study 16918657 — intervention group
Group type: COMPARATOR
Intervention: No muscle relaxant (Group C, n = 60)
Number of subjects: 119
Study 16918657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study 15486330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (structured nurse assessment, education, treatment recommendations)
Number of subjects: 146
Study 15486330 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 146
Study 11374206 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbal label
Number of subjects: 0
Study 11374206 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative verbal label
Number of subjects: 0
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of sinistrin
Number of subjects: 6
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose followed by a 6-hour infusion of sinistrin
Number of subjects: 6
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point method after bolus
Number of subjects: 6
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: D/AUC method with extrapolation to infinity
Number of subjects: 6
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: UV/P method
Number of subjects: 6
Study 9378840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinf/P method
Number of subjects: 6
Study 8475837 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative subconjunctival 5-fluorouracil (5-FU) injections
Number of subjects: 263
Study 8475837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 263
Study 3692037 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening genogram
Number of subjects: 0
Study 3692037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening genogram)
Number of subjects: 0
Study 29446195 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing and cognitive-behavioural therapy
Number of subjects: 0
Study 29446195 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer term motivational interviewing and cognitive-behavioural therapy
Number of subjects: 0
Study 29446195 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 26298842 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentary film about schizophrenia (Film group)
Number of subjects: 49
Study 26298842 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 49
Study 24873088 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium Elastic Nail System (TENS)
Number of subjects: 35
Study 24873088 — intervention group
Group type: COMPARATOR
Intervention: Stainless Steel Elastic Nail System (SSEN)
Number of subjects: 35
Study 21801476 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamins (5-methyl-THF (560 μg); vitamin B₆ (3 mg); vitamin B₁₂ (20 μg))
Number of subjects: 2501
Study 21801476 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (600 mg of EPA and DHA at a ratio of 2:1)
Number of subjects: 2501
Study 21801476 — intervention group
Group type: EXPERIMENTAL
Intervention: Both B-vitamins and n-3 fatty acids
Number of subjects: 2501
Study 21801476 — intervention group
Group type: COMPARATOR
Intervention: Placebo for B-vitamins and n-3 fatty acids
Number of subjects: 2501
Study 21801476 — intervention group
Group type: COMPARATOR
Intervention: Placebo for both treatments
Number of subjects: 2501
Study 20368566 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 U weekly during and after chemotherapy)
Number of subjects: 1379
Study 20368566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379
Study 18394661 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with d-cycloserine
Number of subjects: 0
Study 18394661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 18394661 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 18394661 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 16084429 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 compartment model (2C)
Number of subjects: 77
Study 16084429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 compartment model (3C)
Number of subjects: 77
Study 12196498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 699
Study 12196498 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 699
Study 9987699 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 5
Study 9987699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7778543 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 2800
Study 2320062 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (200 mg, intravenous)
Number of subjects: 10
Study 2320062 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (250 mg three times a day for four weeks)
Number of subjects: 10
Study 7351282 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate with atropine (Lomotil)
Number of subjects: 15
Study 7351282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30170430 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid etching
Number of subjects: 120
Study 30170430 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% phosphoric acid etching
Number of subjects: 120
Study 30170430 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% phosphoric acid etching
Number of subjects: 120
Study 30170430 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond 2 adhesive
Number of subjects: 120
Study 30170430 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning electron microscopy (SEM) analysis
Number of subjects: 120
Study 30170430 — intervention group
Group type: COMPARATOR
Intervention: Comparison of bond strength across fluorosis levels
Number of subjects: 120
Study 27606611 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU)
Number of subjects: 301
Study 27606611 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Radiation
Number of subjects: 301
Study 23999198 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 49
Study 23999198 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 49
Study 23999198 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg and 3.0 mg
Number of subjects: 49
Study 23326985 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made aluminum splint
Number of subjects: 60
Study 23326985 — intervention group
Group type: COMPARATOR
Intervention: Conventional aluminum splint
Number of subjects: 60
Study 20034629 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 14238
Study 18772279 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized visual feedback
Number of subjects: 12
Study 18772279 — intervention group
Group type: COMPARATOR
Intervention: Verbal instructions by the therapist
Number of subjects: 12
Study 18772279 — intervention group
Group type: COMPARATOR
Intervention: No form of feedback
Number of subjects: 12
Study 15962332 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training program (12-week supervised rehabilitation program, cycle exercise at 70% peak work rate, upper-body weight-lifting at 50% maximum capacity)
Number of subjects: 20
Study 15962332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 12668800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 12668800 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 85
Study 12668800 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-occasion measurements
Number of subjects: 85
Study 11196760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric polymaltose (6 mg/kg/d)
Number of subjects: 123
Study 11196760 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (6 mg/kg/d)
Number of subjects: 123
Study 8653568 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane graft (PUR)
Number of subjects: 20
Study 8653568 — intervention group
Group type: COMPARATOR
Intervention: Dacron graft
Number of subjects: 20
Study 1385971 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 10
Study 1385971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 10
Study 1385971 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine 200 mg
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine 400 mg
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine 800 mg
Number of subjects: 6
Study 6147051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (all doses)
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (800 mg)
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (highest dose)
Number of subjects: 6
Study 6147051 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine (400 mg)
Number of subjects: 6
Study 30614901 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 131
Study 29266965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified-dose ICS/LABA
Number of subjects: 450
Study 29266965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 26440923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg vitamin D3 per day
Number of subjects: 90
Study 26591679 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-Medicine
Number of subjects: 126
Study 26591679 — intervention group
Group type: COMPARATOR
Intervention: Medicine
Number of subjects: 126
Study 23180950 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 59
Study 23180950 — intervention group
Group type: COMPARATOR
Intervention: Control monitoring
Number of subjects: 59
Study 20136801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 124
Study 20136801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 20136801 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 124
Study 18383869 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Number of subjects: 0
Study 15793094 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 11
Study 15793094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15793094 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 11
Study 11934246 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded hypokinetic subjects (LHKS)
Number of subjects: 40
Study 11934246 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloaded hypokinetic subjects (UHKS)
Number of subjects: 40
Study 11934246 — intervention group
Group type: COMPARATOR
Intervention: Loaded ambulatory control subjects (LACS)
Number of subjects: 40
Study 11934246 — intervention group
Group type: COMPARATOR
Intervention: Unloaded ambulatory control subjects (UACS)
Number of subjects: 40
Study 10356137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.25 mg/kg
Number of subjects: 20
Study 10356137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10356137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM)
Number of subjects: 20
Study 8619455 — intervention group
Group type: EXPERIMENTAL
Intervention: Meglumine ioxitalamate (100 mL via nasogastric tube)
Number of subjects: 50
Study 8619455 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment without contrast material
Number of subjects: 50
Study 1923175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 71
Study 1923175 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 71
Study 6094458 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 0.5 g single dose
Number of subjects: 281
Study 6094458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 0.5 g twice a day for 10 days
Number of subjects: 281
Study 6094458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g twice or three times a day for 10 days
Number of subjects: 281
Study 31800488 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 18
Study 31800488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mecamylamine
Number of subjects: 18
Study 31800488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 1740
Study 29651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 1740
Study 29651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + surgery
Number of subjects: 1740
Study 29651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + adjuvant chemotherapy
Number of subjects: 1740
Study 29651664 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1740
Study 29651664 — intervention group
Group type: EXPERIMENTAL
Intervention: Any chemotherapy with surgery
Number of subjects: 1740
Study 25630713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 75
Study 25630713 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 75
Study 24269858 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 144
Study 24269858 — intervention group
Group type: COMPARATOR
Intervention: autograft/allograft
Number of subjects: 144
Study 19380753 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily enteral supplementation with zinc, selenium, and glutamine plus parenteral metoclopramide
Number of subjects: 0
Study 19380753 — intervention group
Group type: COMPARATOR
Intervention: Enteral supplementation with whey protein
Number of subjects: 0
Study 15067161 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent management of disability benefits
Number of subjects: 41
Study 15067161 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent management of disability benefits
Number of subjects: 41
Study 11423056 — intervention group
Group type: COMPARATOR
Intervention: 5-mg warfarin group
Number of subjects: 197
Study 11423056 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-mg warfarin group
Number of subjects: 197
Study 11423056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197